Prelude Therapeutics Incorporated (NASDAQ: PRLD)
$6.30
+0.6250 ( +11.02% ) 322.6K
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Market Data
Open
$6.30
Previous close
$5.67
Volume
322.6K
Market cap
$341.11M
Day range
$5.36 - $6.41
52 week range
$1.66 - $6.41
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 08, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
4 | Insider transactions | 1 | Jun 18, 2024 |
8-k | 8K-related | 11 | Jun 18, 2024 |
8-k | 8K-related | 112 | Jun 12, 2024 |
4 | Insider transactions | 1 | May 16, 2024 |